{"id":"W2905822848","doi":"10.1016/j.ejca.2018.11.018","title":"An open-label, multicentre safety study of vemurafenib in patients with BRAFV600-mutant metastatic melanoma: final analysis and a validated prognostic scoring system","year":2018,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":14,"is_retracted":false,"has_abstract":false,"ca_institutions":"McGill University Health Centre","funders":"Merck Sharp and Dohme; EUSA Pharma; Eisai; Genentech; Les Laboratories Pierre Fabre; Regeneron Pharmaceuticals; Chugai Pharmaceutical; Amgen; Pfizer; Bristol-Myers Squibb; F. Hoffmann-La Roche","keywords":"Vemurafenib; Medicine; Internal medicine; Tolerability; Melanoma; Metastatic melanoma; Dacarbazine; Oncology; Clinical trial; Population; Surgery; Adverse effect; Chemotherapy; Cancer research; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003102008,0.001233121,0.001804456,0.0003608968,0.0003824058,0.001164967,0.0006437371,0.0009387275,0.00128669],"category_scores_gemma":[0.003591118,0.000472557,0.002000876,0.0004028539,0.0007760408,0.001330461,0.0004912728,0.001507284,0.0003633451],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008268515,"about_ca_system_score_gemma":0.0006418714,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003961563,"about_ca_topic_score_gemma":0.0006845679,"domain_scores_codex":[0.9987018,0.0006490825,0.00006806332,0.0002666836,0.0001711292,0.0001432332],"domain_scores_gemma":[0.9973743,0.0007268222,0.0006842315,0.0004656185,0.0002786725,0.0004702843],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.8586258,0.004562401,0.07893258,0.0003726199,0.004305572,0.0001975245,0.0002260674,0.00237446,0.0143136,0.0001733046,0.0008153594,0.03510067],"study_design_scores_gemma":[0.3050621,0.2302036,0.4405385,0.00006504071,0.004963874,0.001227475,0.0002797233,0.007900544,0.005477003,0.0007647843,0.003310269,0.0002071328],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9980457,0.0005363545,0.0004540221,0.00004911688,0.00002589636,0.0001644462,0.0004388599,0.00001947486,0.0002660132],"genre_scores_gemma":[0.9976757,0.0001298138,0.0004318891,0.00009627622,0.00004250092,0.0001700016,0.001123586,0.00001160761,0.0003186672],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003102008,"threshold_uncertainty_score":0.01640517,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02297751324771618,"score_gpt":0.2802544449555863,"score_spread":0.2572769317078701,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}